Optical-Spectrometry-Based Method for Immunosuppressant Medicine Level Detection in Aqueous Solutions - Publikacja - MOST Wiedzy


Optical-Spectrometry-Based Method for Immunosuppressant Medicine Level Detection in Aqueous Solutions


In this paper, an investigation into detecting immunosuppressive medicine in aqueous solutions using a spectrometry-based technique is described. Using optical transmissive spectrometry, absorbance measurements in the spectra range from 250 nm to 1000 nm were carried out for different cyclosporine A (CsA) concentrations in aqueous solutions. The experiment was conducted for samples both with and without interferent substances—glucose and sodium chloride. Using a dedicated algorithm, the measured data was analyzed and a high correlation coefficient R2 = 0.8647 was achieved. The experiment showed that the described technique allowed for the detection of various CsA concentration levels in a selective, label-free and simple way. This method could be used in medicine, veterinary medicine and laboratory diagnostics.


  • 1


  • 1

    Web of Science

  • 1


Cytuj jako

Pełna treść

pobierz publikację
pobrano 3 razy
Wersja publikacji
Accepted albo Published Version
Creative Commons: CC-BY otwiera się w nowej karcie

Słowa kluczowe

Informacje szczegółowe

Publikacja w czasopiśmie
artykuł w czasopiśmie wyróżnionym w JCR
Opublikowano w:
SENSORS nr 18, wydanie 7, strony 1 - 9,
ISSN: 1424-8220
Rok wydania:
Opis bibliograficzny:
Marzejon M., Kosowska M., Majchrowicz D., Bułło-Piontecka B., Wąsowicz M., Jędrzejewska-Szczerska M.: Optical-Spectrometry-Based Method for Immunosuppressant Medicine Level Detection in Aqueous Solutions// SENSORS. -Vol. 18, iss. 7 (2018), s.1-9
Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.3390/s18072001
Bibliografia: test
  1. Haschek, W.M.; Rousseaux, C.G.; Wallig, M.A. Chapter 15-Immune System. In Fundamentals of Toxicologic Pathology, 2nd ed.; Academic Press: San Diego, CA, USA, 2010; pp. 451-489, ISBN 978-0-12-370469-6. otwiera się w nowej karcie
  2. Hernández-Martín, A.; Noguera-Morel, L.; Bernardino-Cuesta, B.; Torrelo, A.; Pérez-Martin, M.A.; Aparicio-López, C.; de Lucas-Collantes, C. Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 837-842. [CrossRef] [PubMed] otwiera się w nowej karcie
  3. Chew, A.-L.; Bashir, S.J.; Johnston, A.; Barker, J.N.W.N.; Smith, C.H. The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: A prospective cohort study. J. Dermatol. Treat. 2011, 22, 79-85. [CrossRef] [PubMed] otwiera się w nowej karcie
  4. Griffiths, C.E.M.; Katsambas, A.; Dijkmans, B.A.C.; Finlay, A.Y.; Ho, V.C.; Johnston, A.; Luger, T.A.; Mrowietz, U.; Thestrup-Pedersen, K. Update on the use of ciclosporin in immune-mediated dermatoses. Br. J. Dermatol. 2006, 155 (Suppl. 2), 1-16. [CrossRef] [PubMed] otwiera się w nowej karcie
  5. Walsh, S.B.; Xu, J.; Xu, H.; Kurundkar, A.R.; Maheshwari, A.; Grizzle, W.E.; Timares, L.; Huang, C.C.; Kopelovich, L.; Elmets, C.A.; et al. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: Role of TGFβ signaling pathway. Mol. Carcinog. 2011, 50, 516-527. [CrossRef] [PubMed] otwiera się w nowej karcie
  6. Abikhair, M.; Mitsui, H.; Yanofsky, V.; Roudiani, N.; Ovits, C.; Bryan, T.; Oberyszyn, T.M.; Tober, K.L.; Gonzalez, J.; Krueger, J.G.; et al. Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. JCI Insight 2016, 1, e86434. [CrossRef] [PubMed] otwiera się w nowej karcie
  7. Van der Schaft, J.; van Zuilen, A.D.; Deinum, J.; Bruijnzeel-Koomen, C.A.F.M.; de Bruin-Weller, M.S. Serum creatinine levels during and after long-term treatment with cyclosporine a in patients with severe atopic dermatitis. Acta Derm. Venereol. 2015, 95, 963-967. [CrossRef] [PubMed] otwiera się w nowej karcie
  8. Han, W.; Soltani, K.; Ming, M.; He, Y.-Y. Deregulation of XPC and CypA by cyclosporin A: An immunosuppression-independent mechanism of skin carcinogenesis. Cancer Prev. Res. Phila. Pa 2012, 5, 1155-1162. [CrossRef] [PubMed] otwiera się w nowej karcie
  9. Muellenhoff, M.W.; Koo, J.Y. Cyclosporine and skin cancer: An international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J. Dermatol. Treat. 2012, 23, 290-304. [CrossRef] [PubMed] otwiera się w nowej karcie
  10. Roekevisch, E.; Spuls, P.I.; Kuester, D.; Limpens, J.; Schmitt, J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. J. Allergy Clin. Immunol. 2014, 133, 429-438. [CrossRef] [PubMed] otwiera się w nowej karcie
  11. Van der Schaft, J.; Politiek, K.; van den Reek, J.M.P.A.; Christoffers, W.A.; Kievit, W.; de Jong, E.M.G.J.; Bruijnzeel-Koomen, C.A.F.M.; Schuttelaar, M.L.A.; de Bruin-Weller, M.S. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br. J. Dermatol. 2015, 172, 1621-1627. [CrossRef] [PubMed] otwiera się w nowej karcie
  12. Commission Decision of 20 November 2008 on Guidelines for the Purpose of the Risk-Based Animal Health Surveillance Schemes Provided for in Council Directive 2006/88/EC (Notified under Document Number C(2008) 6787) (Text with EEA relevance) (2008/896/EC). Available online: https://eur-lex.europa.eu/legal- content/EN/ALL/?uri=CELEX%3A32008D0896 (accessed on 6 June 2018). otwiera się w nowej karcie
  13. Council Directive 2006/88/EC of 24 October 2006 on Animal Health Requirements for Aquaculture Animals and Products Thereof, and on the Prevention and Control of Certain Diseases in Aquatic Animals. Available online: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX% 3A32006L0088 (accessed on 6 June 2018). otwiera się w nowej karcie
  14. Legrand, J.-J.; Bouchez, C.; Mimouni, C.; N'Guyen, A.; Bouchard, J.; Ameller, T.; Descotes, J. Immunotoxic effects of cyclophosphamide and cyclosporine in the dog. J. Immunotoxicol. 2013, 10, 90-95. [CrossRef] [PubMed] otwiera się w nowej karcie
  15. Elshama, S.S.; EL-Kenawy, A.E.-M.; Osman, H.-E.H. Histopathological Study of Cyclosporine Pulmonary Toxicity in Rats. Available online: https://www.hindawi.com/journals/jt/2016/2973274/ (accessed on 15 May 2018). otwiera się w nowej karcie
  16. Kovalik, M.; Thoday, K.L.; Handel, I.G.; Bronsvoort, B.M.C.; Evans, H.; van den Broek, A.H.M.; Mellanby, R.J. Ciclosporin A therapy is associated with disturbances in glucose metabolism in dogs with atopic dermatitis. Vet. Dermatol. 2011, 22, 173-180. [CrossRef] [PubMed] otwiera się w nowej karcie
  17. Last, R.D.; Suzuki, Y.; Manning, T.; Lindsay, D.; Galipeau, L.; Whitbread, T.J. A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin A for feline atopy. Vet. Dermatol. 2004, 15, 194-198. [CrossRef] [PubMed] otwiera się w nowej karcie
  18. Bechstein, W.O. Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transpl. Int. Off. J. Eur. Soc. Organ Transplant. 2000, 13, 313-326. [CrossRef] otwiera się w nowej karcie
  19. Gauglitz, G.; Vo-Dinh, T. Handbook of Spectroscopy; Wiley-VCH: Weinheim, Germany, 2003; ISBN 3-527-29782-0.
  20. Benavides, A.L.; Aragones, J.L.; Vega, C. Consensus on the solubility of NaCl in water from computer simulations using the chemical potential route. J. Chem. Phys. 2016, 144, 124504. [CrossRef] [PubMed] otwiera się w nowej karcie
  21. Jørgensen, N.O.G. Carbohydrates. In Encyclopedia of Inland Waters; Academic Press: Oxford, UK, 2009; pp. 727-742, ISBN 978-0-12-370626-3. otwiera się w nowej karcie
  22. Rai, H. Glucose in Freshwater of Central Amazon Lakes: Natural Substrate Concentrations Determined by Dilution Bioassay. Int. Rev. Gesamten Hydrobiol. Hydrogr. 1979, 64, 141-146. [CrossRef] otwiera się w nowej karcie
Politechnika Gdańska

wyświetlono 66 razy

Publikacje, które mogą cię zainteresować

Meta Tagi